SPDR S&P Health Care Equipment ETF (XHE)
- Previous Close
83.19 - Open
83.14 - Bid 83.21 x 1200
- Ask 83.27 x 1300
- Day's Range
83.02 - 83.64 - 52 Week Range
66.20 - 99.68 - Volume
11,172 - Avg. Volume
24,780 - Net Assets 285.74M
- NAV 83.18
- PE Ratio (TTM) 30.55
- Yield 0.03%
- YTD Daily Total Return -1.28%
- Beta (5Y Monthly) 1.15
- Expense Ratio (net) 0.35%
In seeking to track the performance of the S&P Health Care Equipment Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the health care equipment segment of the S&P Total Market Index ("S&P TMI").
SPDR State Street Global Advisors
Fund Family
Health
Fund Category
285.74M
Net Assets
2011-01-26
Inception Date
Performance Overview: XHE
Trailing returns as of 4/23/2024. Category is Health.
People Also Watch
Holdings: XHE
Top 10 Holdings (17.78% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: XHE
Analyst Report: Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice TargetERF: What does Argus have to say about ERF?
ENERPLUS CORP has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetAnalyst Report: ASML Holding N.V.
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s main clients are TSMC, Samsung, and Intel.
RatingPrice TargetERF: What does Argus have to say about ERF?
ENERPLUS CORP has an Investment Rating of SELL; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target